Linköping University Medical Dissertations
No. 793
From achiral to chiral analysis of citalopram
Errata
Page 21, line 7. CYP1A2 shows a great inter-individual variability but it is not
polymorphically expressed, approximately 50 % Caucasians being slow or intermediate metabolizers (Landi et al., 1999).
Page 74, Table 9. Sample number Cit Total concentration nmol/L (µg/g) S/R Ratio DCit Total concentration nmol/L (µg/g) S/R Ratio DDCit Total concentration nmol/L (µg/g) S/R Ratio 1 2472 (0.80) 1.03 318 (0.097) 1.37 43 (0.013) 2.07 2 981 (0,32) 0.94 198 (0.061) 0.92 <2 3 1591 (0.52) 0.99 239 (0.074) 1.88 23 (0.007) Only S-DDCit 4 640 (0.21) 0.90 115 (0.036) 0.69 <2 5 1188 (0.39) 0.89 191 (0.059) 0.84 15 (0.004) 1.14 6 2484 (0.81) 1.14 172 (0.053) 1.00 <2
Paper I, page 235, second column. 2.3 Chromatographic conditions. The mobile
phase was acetonitrile-70 mmol/L phosphate buffer (40:60) pH 4.5 …
Paper III, page 660, second column, line 1. The limits of quantification for the
enantiomers of CIT and metabolites were 2 nmol/L (S/N 10:1) Page 661, TABLE 2, Daily citalopram dose (mg)
Page 662, second column, line 14. CIT enantiomers (12,32)
Paper IV Accepted for publication in Journal of Analytical Toxicology
Page 4, line 16. CYP2D6*2 not CYP2D6*2+, 2850C>T not C2931T Line 17 and 18. CYP2D6*3 (2549A>del) and CYP2D6*4 (1846G>A) Page 11, Table 3. Raw 12 CYP2D6, and *2 not *2+.
Appendix, page 91.
N=16(tR/w) 2
